Skip to content

Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery

'All Comer'/'Real-world' Registry-based Randomized, Prospective, Multicenter Clinical Trial to Evaluate the Incidence of Complications Using Novosyn® CHD Suture Versus Polyglactin 910 Suture to Close the Wound After Emergency or Elective Laparotomy or Laparoscopic Surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05966961
Acronym
POLYNOVO-CHD
Enrollment
2998
Registered
2023-08-01
Start date
2023-09-18
Completion date
2028-12-01
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection

Keywords

Chlorhexidine coated suture, emergency laparoscopic surgery, emergency laparotomy surgery, elective laparoscopic surgery, elective laparotomy surgery, Novosyn®, Polyglactin 910

Brief summary

The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will generate further clinical evidence for the use and the benefit of a Chlorhexidine coated suture used to close the wound after an emergency or elective laparoscopic or laparotomy surgery. The benefit for individual patients lies in the early diagnosis of complications and in the optimized postoperative controls of a clinical study.

Interventions

DEVICENovosyn® in emergency or elective laparotomy or laparoscopic surgery

Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

DEVICEPolyglactin 910 in emergency or elective laparotomy or laparoscopic surgery

Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

Sponsors

Aesculap AG
Lead SponsorINDUSTRY
B.Braun Surgical SA
CollaboratorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing an emergency or elective laparotomy or laparoscopic surgery. * Written informed consent * Age≥ 18 years * Not incapacitated patient

Exclusion criteria

* No

Design outcomes

Primary

MeasureTime frameDescription
Frequency of surgical site infection (superficial (A1) and deep (A2)until 30 days + 5 days after surgery.The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2).

Secondary

MeasureTime frameDescription
Handling of the suture materialintraoperativelyAssessment of the handling of the suture material intraoperatively using a questionnaire including different dimensions (knot security, tensile strength, knot run down, tissue drag etc.) with 5 evaluations levels (excellent, very good, good, satisfied, poor).
Length of hospital stayuntil discharge (approximately 10 days after surgery)Number of days the patient has to stay in hospital after emergency or elective laparotomy or laparoscopic surgery
Time to return to workuntil 30 days + 5 days after surgery.Number of days the patient needed to return to work after emergency or elective laparotomy or laparoscopic surgery
Incidence of Surgical Site Infection (SSI)at discharge (approximately 10 days after surgery)Incidence of Surgical Site Infection (SSI) (superficial (A1), deep (A2) and organ space (A3)) at the time of discharge
Incidence of SSI (superficial (A1), deep (A2) and organ space (A3)) stratified by wound classuntil 30 days + 5 days after surgeryIncidence of SSI (superficial (A1), deep (A2) and organ space (A3)) stratified by wound class (Class I clean, Class II clean/contaminated, Class III contaminated, Class IV dirty/infected)
Cumulative Rate of postoperative complicationsdischarge (approximately 10 days after surgery) and 30 days+ 5 days after surgery.Number of postoperative complications of any kind for descriptive analysis
Cumulative Rate of reoperationat discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.Number of reoperation of any kind for descriptive analysis
Cumulative Rate of suture removal due to wound problemsat discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.Rate of suture removal due to wound problems (infection, dehiscence, residual material requiring removal) for descriptive analysis
Cumulative Rate of Re-suturingat discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.Rate of Re-suturing of any kind for descriptive analysis
Hernia rate30 days + 5 days postoperativelyNumber of Wound Hernia including umbilical hernia verified by ultra-sound examination

Countries

Italy, Spain

Contacts

CONTACTJaume Garcia Lopez
info@bbraun.com+34935866200
CONTACTRicard Rosique
info@bbraun.com
PRINCIPAL_INVESTIGATORAntonio José Torres Garcia, Prof. Dr.

Hospital San Carlos, Madrid

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026